Optune Therapy

Alternating electric field therapy, sometimes called tumor treating fields, or TTFields, is a type of electromagnetic field therapy using low-intensity electrical fields to treat cancer.

A TTF-generating device called Optune is manufactured by the company, Novocure. Optune is approved in the United States and Europe for the treatment of newly diagnosed and recurrent glioblastoma multiforme, or GBM, and is undergoing clinical trials for several other tumor types.

Optune Therapy Clinical Trials

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

CONTACT:
Sonisha A. Warren, PhD
Phone:352.294.8737
Email: sonisha.warren@neurosurgery.ufl.edu

2-THE-TOP: Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

CONTACT:
Sonisha A. Warren, PhD
Phone:352.294.8737
Email: sonisha.warren@neurosurgery.ufl.edu

PRECISION: A Phase II Study of the Optune System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma Multiforme

CONTACT:
Sonisha A. Warren, PhD
Phone:352.294.8737
Email: sonisha.warren@neurosurgery.ufl.edu

FORWARD: A Phase 2, Historically Controlled Study Testing the Efficacy of TTFields (Optune®) With Adjuvant Temozolomide in High Risk WHO Grade II and III Astrocytomas (FORWARD)

CONTACT:
Annie Allen, MBA
Phone:352.294.8836
Email: Forward-Study@ufl.edu

What is Optune?

Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM tumor is located.

Optune delivers therapy through 4 adhesive patches, called transducer arrays. These transducer arrays are applied to your scalp and are connected to the device and battery.